Added to YB: 2026-06-11
Pitch date: 2026-06-09
ENGN [bullish]
enGene Therapeutics Inc.
-4.19%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
Market Cap
$111.9M
Pitch Price
$1.67
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
N/A
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Free Demo of New Special Situations Tool and Stock Trade Compilation Episode Ocho - $ENGN
ENGN: Failed biotech post-80% drop after Phase 2 interim flop; trading below excess cash on balance sheet. Activist BML Investment Partners took 10% stake; CMO given exit parachute signaling potential wind-down. Author bought cheap & sold OTM calls.
Read full article (1 min)